business
BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
Key takeaways
- A dose bottle of the medication is in the medical tech s hand
- The pressure point is Boston Scientific Corporation (NYSE:BSX)’s Watchman left atrial appendage closure franchise, where management recently signaled reduced growth expectations over the next couple of quarters.
- On June 1, 2026, Canaccord also trimmed its price target, to $70 from $71, while keeping a “Buy” rating.
BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock Faheem Tahir Thu, June 11, 2026 at 8:03 PM GMT+7 2 min read BSX With a forward P/E of 14.45x and upside potential of 59.60%, Boston Scientific Corporation (NYSE:BSX) ranks among the top 10 lowest forward P/E stocks in the S&P 500.
A dose bottle of the medication is in the medical tech s hand
Boston Scientific Corporation (NYSE:BSX) has seen a sharp de-rating in 2026, with shares down nearly 50% year-to-date as of June 8, 2026, even as the vast majority of covering analysts maintain bullish ratings on the stock.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop